Clinical Trial Update: SHR-1210 in Combination With GEMOX in Patients With Advanced BTC [Phase 2]

View source ↗

Summary

Phase 2 trial of SHR-1210 combined with GEMOX in advanced biliary tract cancer and cholangiocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Status: COMPLETED